Skip to main content
. Author manuscript; available in PMC: 2013 Mar 22.
Published in final edited form as: Curr Pharm Des. 2012;18(9):1199–1216. doi: 10.2174/138161212799436421

Fig. 12.

Fig. 12

Overlaid CypA and CypB active sites with inhibitor 3a bound at the active sites as predicted by BOMB. Nearby waters removed for clarity. The lighter colored structure is the preferred binding conformation in CypA and the darker structure is favored in CypB.